New Phenylspirodrimanes from the Sponge-Associated Fungus Stachybotrys chartarum MUT 3308

Mar Drugs. 2023 Feb 21;21(3):135. doi: 10.3390/md21030135.

Abstract

Two phenylspirodrimanes, never isolated before, stachybotrin J (1) and new stachybocin G (epi-stachybocin A) (2), along with the already reported stachybotrin I (3), stachybotrin H (4), stachybotrylactam (5), stachybotrylactam acetate (6), 2α-acetoxystachybotrylactam acetate (7), stachybotramide (8), chartarlactam B (9), and F1839-J (10) were isolated from the sponge-associated fungus Stachybotrys chartarum MUT 3308. Their structures were established based on extensive spectrometric (HRMS) and spectroscopic (1D and 2D NMR) analyses. Absolute configurations of the stereogenic centers of stachybotrin J (1), stachybocin G (2), and stachybotrin I (3), were determined by comparison of their experimental circular dichroism (CD) spectra with their time-dependent density functional theory (TD-DFT) circular dichroism (ECD) spectra. The putative structures of seventeen additional phenylspirodrimanes were proposed by analysis of their respective MS/MS spectra through a Feature-Based Molecular Networking approach. All the isolated compounds were evaluated for their cytotoxicity against five aggressive cancer cell lines (MP41, 786, 786R, CAL33, and CAL33RR), notably including two resistant human cancer cell lines (786R, CAL33RR), and compounds 5, 6, and 7 exhibited cytotoxicity with IC50 values in the range of 0.3-2.2 µM.

Keywords: Stachybotrys chartarum; cytotoxicity; isolation; marine fungus; phenylspirodrimanes.

MeSH terms

  • Cell Line
  • Humans
  • Molecular Structure
  • Stachybotrys*
  • Tandem Mass Spectrometry*

Supplementary concepts

  • Stachybotrys chartarum

Grants and funding

This work has been supported by the French government, through the UCAJEDI Investments in the Future project managed by the National Research Agency (ANR) with the reference number ANR-15-IDEX-01 and the FINNOVER project (Strategie Innovative per lo Sviluppo di Filiere Verdi Transfrontaliere)—Interreg Alcotra Italy-France European cross-border program 2014–2020, grant number 1198. We thank the Canceropôle Provence-Alpes-Côte d’Azur, and the Provence-Alpes-Côte d’Azur Region for the financial support provided to the MetaboCell and MetaboPure projects. This publication is based upon work from COST Action CA18238 (Ocean4Biotech) supported by the COST (European Cooperation in Science and Technology) program. E.S. and M.D. (Marie Dayras) are recipients of thesis grants from the “Conseil Regional Provence-Alpes-Côte d’Azur”.